Analyst Price Targets — FENC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 22, 2026 10:11 am | — | H.C. Wainwright | $16.00 | $9.97 | TheFly | Fennec price target raised to $16 from $13 at H.C. Wainwright |
| January 8, 2026 10:30 pm | — | Piper Sandler | $18.00 | $7.58 | TheFly | Fennec initiated with an Overweight at Piper Sandler |
| August 15, 2025 1:03 pm | Chase Knickerbocker | Craig-Hallum | $14.00 | $8.54 | TheFly | Fennec price target raised to $14 from $13 at Craig-Hallum |
| May 15, 2024 8:57 am | Chase Knickerbocker | Craig-Hallum | $17.00 | $7.34 | TheFly | Fennec price target lowered to $17 from $20 at Craig-Hallum |
| May 15, 2024 7:22 am | Raghuram Selvaraju | H.C. Wainwright | $15.00 | $7.03 | StreetInsider | Fennec Pharmaceuticals Inc. (FENC) PT Lowered to $15 at H.C. Wainwright |
| April 4, 2024 6:11 am | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $10.77 | TheFly | Fennec price target raised to $18 from $17 at H.C. Wainwright |
| March 19, 2024 9:31 am | Chase Knickerbocker | Craig-Hallum | $18.00 | $11.01 | StreetInsider | Fennec Pharmaceuticals Inc. (FENC) PT Raised to $18 at Craig-Hallum |
| November 22, 2022 8:25 am | — | Cantor Fitzgerald | $12.00 | $9.17 | Benzinga | Cantor Fitzgerald Upgrades Fennec Pharmaceuticals to Overweight, Raises Price Target to $12 |
| September 26, 2022 10:01 am | — | Wedbush | $19.00 | $7.11 | Benzinga | Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $19 |
Latest News for FENC
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's common shares to one…
RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 10,000 of the Company's common shares to one…
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.
Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FENC.
U.S. House Trading
No House trades found for FENC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.